Summary of Study ST002711

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001606. The data can be accessed directly via it's Project DOI: 10.21228/M83T4M This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002711
Study TitleMetabolomic analysis of maternal mid-gestation plasma and cord blood: biogenic amines
Study SummaryMetabolomic analysis of maternal mid-gestation plasma and cord blood reveals evidence in autism spectrum disorder of inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. The discovery of prenatal and neonatal molecular biomarkers has the potential to yield insights into autism spectrum disorder (ASD) and facilitate early diagnosis. We characterized metabolomic profiles in ASD using plasma samples collected in the Norwegian Autism Birth Cohort from mothers at weeks 17-21 gestation (maternal mid-gestation, MMG, n=408) and from children on the day of birth (cord blood, CB, n=418). We analyzed associations using sex-stratified adjusted logistic regression models with Bayesian analyses. Chemical enrichment analyses (ChemRICH) were performed to determine altered chemical clusters. We also employed machine learning algorithms to assess the utility of metabolomics as ASD biomarkers. We identified ASD associations with a variety of chemical compounds including arachidonic acid, glutamate, and glutamine, and metabolite clusters including hydroxy eicospentaenoic acids, phosphatidylcholines, and ceramides in MMG and CB plasma that are consistent with inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. Girls with ASD have disruption of ether/non-ether phospholipid balance in the MMG plasma that is similar to that found in other neurodevelopmental disorders. ASD boys in the CB analyses had the highest number of dysregulated chemical clusters. Machine learning classifiers distinguished ASD cases from controls with AUC values ranging from 0.710 to 0.853. Predictive performance was better in CB analyses than in MMG. These findings may provide new insights into the sex-specific differences in ASD and have implications for discovery of biomarkers that may enable early diagnosis and intervention.
Institute
Columbia University
DepartmentCenter for Infection and Immunity
LaboratoryCenter for Infection and Immunity
Last NameLipkin
First NameW. Ian
Address722 W. 168th St., 17th Floor, New York, NY, 10032
Emailwil2001@cumc.columbia.edu
Phone(212) 342-9033
Submit Date2023-05-19
Raw Data AvailableYes
Raw Data File Type(s)d
Analysis Type DetailLC-MS
Release Date2023-07-02
Release Version1
W. Ian Lipkin W. Ian Lipkin
https://dx.doi.org/10.21228/M83T4M
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001606
Project DOI:doi: 10.21228/M83T4M
Project Title:Metabolomic analysis of maternal mid-gestation plasma and cord blood
Project Summary:Metabolomic analysis of maternal mid-gestation plasma and cord blood reveals evidence in autism spectrum disorder of inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. The discovery of prenatal and neonatal molecular biomarkers has the potential to yield insights into autism spectrum disorder (ASD) and facilitate early diagnosis. We characterized metabolomic profiles in ASD using plasma samples collected in the Norwegian Autism Birth Cohort from mothers at weeks 17-21 gestation (maternal mid-gestation, MMG, n=408) and from children on the day of birth (cord blood, CB, n=418). We analyzed associations using sex-stratified adjusted logistic regression models with Bayesian analyses. Chemical enrichment analyses (ChemRICH) were performed to determine altered chemical clusters. We also employed machine learning algorithms to assess the utility of metabolomics as ASD biomarkers. We identified ASD associations with a variety of chemical compounds including arachidonic acid, glutamate, and glutamine, and metabolite clusters including hydroxy eicospentaenoic acids, phosphatidylcholines, and ceramides in MMG and CB plasma that are consistent with inflammation, disruption of membrane integrity, and impaired neurotransmission and neurotoxicity. Girls with ASD have disruption of ether/non-ether phospholipid balance in the MMG plasma that is similar to that found in other neurodevelopmental disorders. ASD boys in the CB analyses had the highest number of dysregulated chemical clusters. Machine learning classifiers distinguished ASD cases from controls with AUC values ranging from 0.710 to 0.853. Predictive performance was better in CB analyses than in MMG. These findings may provide new insights into the sex-specific differences in ASD and have implications for discovery of biomarkers that may enable early diagnosis and intervention.
Institute:Columbia University
Department:Center for Infection and Immunity
Laboratory:Center for Infection and Immunity
Last Name:Lipkin
First Name:W. Ian
Address:722 W. 168th St., 17th Floor, New York, NY, 10032
Email:wil2001@cumc.columbia.edu
Phone:(212) 342-9033

Subject:

Subject ID:SU002816
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sex
SA272430CB-272_BLANKBLANK | Diagnosis:BLANK
SA272431CB-340_ABC-19850Female | Diagnosis:CASE
SA272432CB-99_ABC-21007Female | Diagnosis:CASE
SA272433MMG-276_ABC-16602Female | Diagnosis:CASE
SA272434CB-348_ABC-3414Female | Diagnosis:CASE
SA272435CB-91_ABC-20531Female | Diagnosis:CASE
SA272436CB-356_ABC-21537Female | Diagnosis:CASE
SA272437CB-331_ABC-3681Female | Diagnosis:CASE
SA272438MMG-286_ABC-21479Female | Diagnosis:CASE
SA272439CB-109_ABC-17316Female | Diagnosis:CASE
SA272440CB-305_ABC-19047Female | Diagnosis:CASE
SA272441MMG-367_ABC-19714Female | Diagnosis:CASE
SA272442CB-315_ABC-21823Female | Diagnosis:CASE
SA272443MMG-268_ABC-9987Female | Diagnosis:CASE
SA272444CB-323_ABC-16329Female | Diagnosis:CASE
SA272445CB-366_ABC-18738Female | Diagnosis:CASE
SA272446CB-407_ABC-17540Female | Diagnosis:CASE
SA272447CB-74_ABC-19756Female | Diagnosis:CASE
SA272448MMG-250_ABC-11191Female | Diagnosis:CASE
SA272449CB-417_ABC-17759Female | Diagnosis:CASE
SA272450CB-66_ABC-19930Female | Diagnosis:CASE
SA272451MMG-7_ABC-19205Female | Diagnosis:CASE
SA272452CB-399_ABC-20769Female | Diagnosis:CASE
SA272453CB-391_ABC-20870Female | Diagnosis:CASE
SA272454CB-382_ABC-11725Female | Diagnosis:CASE
SA272455CB-374_ABC-20952Female | Diagnosis:CASE
SA272456CB-168_ABC-21528Female | Diagnosis:CASE
SA272457MMG-377_ABC-20867Female | Diagnosis:CASE
SA272458MMG-258_ABC-5893Female | Diagnosis:CASE
SA272459MMG-178_ABC-20900Female | Diagnosis:CASE
SA272460MMG-294_ABC-16796Female | Diagnosis:CASE
SA272461CB-150_ABC-21476Female | Diagnosis:CASE
SA272462CB-201_ABC-21318Female | Diagnosis:CASE
SA272463CB-211_ABC-3138Female | Diagnosis:CASE
SA272464CB-220_ABC-17926Female | Diagnosis:CASE
SA272465CB-142_ABC-20956Female | Diagnosis:CASE
SA272466MMG-322_ABC-2836Female | Diagnosis:CASE
SA272467MMG-331_ABC-17760Female | Diagnosis:CASE
SA272468MMG-349_ABC-17697Female | Diagnosis:CASE
SA272469CB-176_ABC-17482Female | Diagnosis:CASE
SA272470MMG-341_ABC-2262Female | Diagnosis:CASE
SA272471CB-185_ABC-19283Female | Diagnosis:CASE
SA272472CB-160_ABC-7113Female | Diagnosis:CASE
SA272473CB-193_ABC-20903Female | Diagnosis:CASE
SA272474CB-228_ABC-2200Female | Diagnosis:CASE
SA272475CB-237_ABC-21076Female | Diagnosis:CASE
SA272476CB-271_ABC-19465Female | Diagnosis:CASE
SA272477CB-125_ABC-18756Female | Diagnosis:CASE
SA272478CB-280_ABC-10358Female | Diagnosis:CASE
SA272479CB-289_ABC-2180Female | Diagnosis:CASE
SA272480MMG-385_ABC-20792Female | Diagnosis:CASE
SA272481CB-117_ABC-17438Female | Diagnosis:CASE
SA272482MMG-304_ABC-21723Female | Diagnosis:CASE
SA272483MMG-359_ABC-20950Female | Diagnosis:CASE
SA272484CB-134_ABC-4344Female | Diagnosis:CASE
SA272485CB-245_ABC-4191Female | Diagnosis:CASE
SA272486MMG-312_ABC-16673Female | Diagnosis:CASE
SA272487CB-253_ABC-20046Female | Diagnosis:CASE
SA272488CB-263_ABC-11634Female | Diagnosis:CASE
SA272489CB-297_ABC-21684Female | Diagnosis:CASE
SA272490CB-83_ABC-16997Female | Diagnosis:CASE
SA272491MMG-95_ABC-19458Female | Diagnosis:CASE
SA272492MMG-87_ABC-21004Female | Diagnosis:CASE
SA272493MMG-240_ABC-19632Female | Diagnosis:CASE
SA272494MMG-105_ABC-19926Female | Diagnosis:CASE
SA272495MMG-204_ABC-16430Female | Diagnosis:CASE
SA272496MMG-214_ABC-10032Female | Diagnosis:CASE
SA272497MMG-77_ABC-18778Female | Diagnosis:CASE
SA272498MMG-222_ABC-21073Female | Diagnosis:CASE
SA272499MMG-393_ABC-11918Female | Diagnosis:CASE
SA272500MMG-69_ABC-18865Female | Diagnosis:CASE
SA272501CB-40_ABC-19202Female | Diagnosis:CASE
SA272502MMG-113_ABC-19438Female | Diagnosis:CASE
SA272503MMG-123_ABC-16993Female | Diagnosis:CASE
SA272504MMG-186_ABC-20853Female | Diagnosis:CASE
SA272505MMG-149_ABC-5666Female | Diagnosis:CASE
SA272506MMG-159_ABC-19881Female | Diagnosis:CASE
SA272507CB-7_ABC-2298Female | Diagnosis:CASE
SA272508MMG-168_ABC-19407Female | Diagnosis:CASE
SA272509CB-15_ABC-21379Female | Diagnosis:CASE
SA272510MMG-141_ABC-21970Female | Diagnosis:CASE
SA272511CB-23_ABC-18908Female | Diagnosis:CASE
SA272512MMG-401_ABC-16983Female | Diagnosis:CASE
SA272513MMG-196_ABC-2332Female | Diagnosis:CASE
SA272514MMG-131_ABC-20953Female | Diagnosis:CASE
SA272515MMG-59_ABC-16904Female | Diagnosis:CASE
SA272516CB-32_ABC-3185Female | Diagnosis:CASE
SA272517CB-58_ABC-19574Female | Diagnosis:CASE
SA272518MMG-23_ABC-2299Female | Diagnosis:CASE
SA272519MMG-33_ABC-2881Female | Diagnosis:CASE
SA272520MMG-41_ABC-19210Female | Diagnosis:CASE
SA272521MMG-232_ABC-17671Female | Diagnosis:CASE
SA272522MMG-51_ABC-17221Female | Diagnosis:CASE
SA272523CB-48_ABC-16466Female | Diagnosis:CASE
SA272524MMG-15_ABC-19050Female | Diagnosis:CASE
SA272525CB-221_ABC-8651Female | Diagnosis:CONTROL
SA272526CB-418_ABC-10990Female | Diagnosis:CONTROL
SA272527MMG-323_ABC-17707Female | Diagnosis:CONTROL
SA272528MMG-142_ABC-7591Female | Diagnosis:CONTROL
SA272529MMG-132_ABC-10400Female | Diagnosis:CONTROL
Showing page 1 of 11     Results:    1  2  3  4  5  Next  Last     Showing results 1 to 100 of 1088

Collection:

Collection ID:CO002809
Collection Summary:spun inside centrifuge and processed
Sample Type:Blood (plasma)

Treatment:

Treatment ID:TR002825
Treatment Summary:NA

Sample Preparation:

Sampleprep ID:SP002822
Sampleprep Summary:SOP blood-LCGCextract-02252019

Combined analysis:

Analysis ID AN004393 AN004394
Analysis type MS MS
Chromatography type HILIC HILIC
Chromatography system Agilent 1290 Infinity Agilent 1290 Infinity
Column Waters ACQUITY UPLC BEH C18 (50 x 2.1mm,1.7um) Waters ACQUITY UPLC BEH C18 (50 x 2.1mm,1.7um)
MS Type ESI ESI
MS instrument type QTOF QTOF
MS instrument name Agilent 6530 QTOF Agilent 6550 QTOF
Ion Mode POSITIVE NEGATIVE
Units normalized peak heights normalized peak heights

Chromatography:

Chromatography ID:CH003296
Instrument Name:Agilent 1290 Infinity
Column Name:Waters ACQUITY UPLC BEH C18 (50 x 2.1mm,1.7um)
Column Temperature:45°C
Flow Gradient:0 min, 100% B; 0.5 min, 100% B; 1.95 min, 70% B; 2.55 min, 30% B; 3.15 min, 100% B; 3.8 min, 100% B
Flow Rate:0.8 mL/min
Solvent A:100% water; 10 mM ammonium formate + 0.125% formic acid, pH 3
Solvent B:95% acetonitrile/5% water; 10 mM ammonium formate; 0.125% formic acid, pH 3
Chromatography Type:HILIC

MS:

MS ID:MS004142
Analysis ID:AN004393
Instrument Name:Agilent 6530 QTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:The quadrupole/time-of-flight (QTOF) mass spectrometers are operated with electrospray ionization (ESI) performing full scan in the mass range m/z 65–1700 in positive (Agilent 6530, equipped with a JetStreamSource) and negative (Agilent 6550, equipped with a dual JetStream Source) modes producing both unique and complementary spectra. Instrument parameters are as follows (positive mode) Gas Temp 325°C, Gas Flow 8 l/min, Nebulizer 35 psig, Sheath Gas 350°C, Sheath Gas Flow 11, Capillary Voltage 3500 V, Nozzle Voltage 1000V, Fragmentor 120V, Skimmer 65V. Data (both profile and centroid) are collected at a rate of 2 scans per second. In negative ion mode, Gas Temp 200°C, Gas Flow 14 l/min, Fragmentor 175V, with the other parameters identical to positive ion mode. For the 6530 QTOF, a reference solution generating ions of 121.050 and 922.007 m/z in positive mode and 119.036 and 966.0007 m/z in negative mode, and these are used for continuous mass correction. For the 6550, the reference solution is introduced via a dual spray ESI, with the same ions and continuous mass correction
Ion Mode:POSITIVE
  
MS ID:MS004143
Analysis ID:AN004394
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:The quadrupole/time-of-flight (QTOF) mass spectrometers are operated with electrospray ionization (ESI) performing full scan in the mass range m/z 65–1700 in positive (Agilent 6530, equipped with a JetStreamSource) and negative (Agilent 6550, equipped with a dual JetStream Source) modes producing both unique and complementary spectra. Instrument parameters are as follows (positive mode) Gas Temp 325°C, Gas Flow 8 l/min, Nebulizer 35 psig, Sheath Gas 350°C, Sheath Gas Flow 11, Capillary Voltage 3500 V, Nozzle Voltage 1000V, Fragmentor 120V, Skimmer 65V. Data (both profile and centroid) are collected at a rate of 2 scans per second. In negative ion mode, Gas Temp 200°C, Gas Flow 14 l/min, Fragmentor 175V, with the other parameters identical to positive ion mode. For the 6530 QTOF, a reference solution generating ions of 121.050 and 922.007 m/z in positive mode and 119.036 and 966.0007 m/z in negative mode, and these are used for continuous mass correction. For the 6550, the reference solution is introduced via a dual spray ESI, with the same ions and continuous mass correction
Ion Mode:NEGATIVE
  logo